Development of innovative children's probiotic with strong inhibition against disease causing microorganisms, based on pure organic ingredients

The ProViotic project will be the invention of a new type of probiotic product that is made of 100% bio-ingredients and at the same time it has strong inhibitory qualities against pathogenic bacteria such as E. coli, Salmonella, and especially H. pylori. More than 50% of the world population today carries H. pylori, while according to leading medical institutions H. pylori can be found in 99% of the duodenal ulcer patients, and 80% of the patients that have stomach cancer. Unfortunately there are not recognizable symptoms, that can signal for the start of the infection with this bacteria, and since its current treatment is based on heavy antibiotics, usually patients start their treatment only after the bacteria has caused a disease. Especially with children, this can be a significant issue, because overexposure to antibiotics can lead to antibiotic resistance that can have significant consequences later in life. However, instead of the antibiotic treatment, we envision to have organic product based on L. bulgaricus GLB44 that is not only a cure against H. pylori infection but also supports the healthy gut flora. This new children’s probiotic can be used also as a preventative support, since it does not have any side effects or overdose. This product will be suitable for children over 1 year old and in addition to eliminate the risk of H. pylori, it will support their digestive and immune systems. Also the product will be able to be used as a post antibiotic treatment, but even in this more regular use, the innovative element will be that it will not contain a single artificial ingredient nor any of the eight major allergens (incl. gluten, lactose, or soy). It will be certified as organic and it will have proven strong antimicrobial effect against H. pylori.

Comments
Leave a comment

Overview

Status Closed (completion date)
Start date 31 Jul, 2017
End date 19 Nov, 2019
Contract date 31 Jul, 2017
View in UMIS

Beneficiary

Financial information

Total cost 429,173.60
Grant 386,256.24
Self finance 42,917.36
Total paid 381,187.22
EU participation percent 85.0%

Location